vida: extract claims from 2026-04-29-cost-plus-drugs-humana-pbm-market-2026

- Source: inbox/queue/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -11,7 +11,7 @@ sourced_from: health/2026-04-28-glp1-managed-access-operating-systems-payer-infr
 scope: structural
 sourcer: on/healthcare.tech
 challenges: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
-related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035"]
+related: ["glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035", "manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression"]
 ---
 
 # Manufacturer direct-to-employer GLP-1 channels launched 2026 represent structural challenge to PBM intermediation by offering 55-60 percent price compression while bypassing traditional pharmacy benefit architecture
@@ -39,3 +39,10 @@ But the structural challenge is real: if manufacturers can profitably deliver GL
 **Source:** PHTI December 2025 employer report
 
 Eli Lilly Employer Connect launched March 5, 2026 at $449/dose with partnerships across 15+ program administrators (GoodRx, Teladoc, Calibrate, Form Health, Waltz). Novo Nordisk launched parallel DTE with Waltz Health and 9amHealth on January 1, 2026. Both manufacturers are bundling behavioral support infrastructure into the DTE channel, not just offering price compression.
+
+
+## Extending Evidence
+
+**Source:** Medical Economics / Drug Channels, 2025-2026
+
+Cost Plus Drugs expanded into 'end-to-end employer prescription solutions' through the Humana partnership, representing another direct-to-employer channel. However, the company's market position remains marginal (Big Three PBMs control 80% of claims) and it operates through partnership with an incumbent rather than pure disintermediation. This suggests direct-to-employer channels are real but structurally limited without incumbent cooperation.

entities/health/cost-plus-drug-company.md

@@ -0,0 +1,43 @@
+# Cost Plus Drug Company
+
+**Type:** Pharmacy / Drug Pricing Platform  
+**Founded:** 2022  
+**Location:** Dallas, TX  
+**Founder:** Mark Cuban  
+**Model:** Acquisition cost + 15% fixed fee (pass-through pricing)  
+
+## Overview
+
+Cost Plus Drug Company operates a direct-to-consumer pharmacy offering transparent pricing on 2,300+ medications, primarily generics. The company's model charges acquisition cost plus a fixed 15% markup, positioning itself as an alternative to traditional PBM-intermediated drug distribution.
+
+## Business Model
+
+- **Pricing:** Cost + 15% fee (transparent pass-through)
+- **Formulary:** 2,300+ medications, mostly generics
+- **Distribution:** Partnership with Humana CenterWell Pharmacy (2025)
+- **Target Market:** Direct-to-consumer, expanding to employer prescription solutions
+- **Next Phase:** Biosimilar portfolio expansion, US manufacturing
+
+## Market Position
+
+- **Competitive Context:** Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) control ~80% of US prescription claims
+- **Strategy:** Partnership with incumbents (Humana) rather than pure disruption
+- **Political Role:** Mark Cuban testified at congressional hearings, supported FTC PBM investigations
+
+## Timeline
+
+- **2022** — Company founded by Mark Cuban
+- **2025-11** — Partnership announced with Humana CenterWell Pharmacy for employer prescription solutions
+- **2026** — Pursuing US manufacturing expansion, generic drug fee waivers
+
+## Limitations
+
+- Primarily generic drugs (doesn't address branded/biologic margins)
+- Distribution dependent on incumbent partnerships
+- No clinical services layer (drug pricing tool, not care delivery)
+
+## Sources
+
+- Medical Economics, November 2025
+- Drug Channels, February 2026
+- Pharmaceutical Commerce, 2025-2026

inbox/archive/health/2026-04-29-cost-plus-drugs-humana-pbm-market-2026.md

@@ -7,10 +7,13 @@ date: 2025-11-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-29
 priority: low
 tags: [pharmacy-benefits, PBM, Cost-Plus-Drugs, market-competition, drug-pricing, structural-reform]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content